Michael Chiorean, MD, AGAF, FACG, Virginia Mason Medical Center, Seattle, Washington, discusses optimal and future use of JAK inhibitors for managing irritable bowel disease. He discusses the mechanism of action of JAK inhibitors and how the selectivity of the inhibitors may be important for safety and efficacy in patients with IBD. Dr Chiorean also reviews safety and clinical data of JAK inhibitors.